The presence and distribution of high risk HPV types in simultaneous cervical cytology samples

Creative Commons License

Aydoğan S., Yazgan A., TAŞ E. E., Gözalan A., YAVUZ A. F., AÇIKGÖZ Z.

Turk Hijyen ve Deneysel Biyoloji Dergisi, vol.75, no.1, pp.13-20, 2018 (Scopus) identifier


© 2018, Refik Saydam National Public Health Agency (RSNPHA).Objective: Human papillomavirus (HPV) is the most detected viral pathogen of reproductive system and almost all servical carsinomas are related to HPV. The incidance and mortality rate of cervical carsinomas are significantly decrease by means of early diagnosis and treatment owing to servical cancer screening programmes. The aim of the study is to evaluate the results of HPV DNA tests and cervical cytology specimens simultaneously in a three year period. Methods: The test results of 328 patients that were send to determine Molecular Microbiology Laboratory for HPV DNA and genotype between 2012-2014 were retrospectively analysed. Moreover, the cytology results of the same patient group were reviewed simultaneously by pathologist and reexamined if necessary. The relationship between cervical anomalies and the presence of HPV DNA and genotypes were exhibited. Cervical samples were collected in DigeneHC2 DNA Collection Device and DNA was isolated using QIAamp DNA Mini Kit. DNA samples were tested for high risk HPV infection by the Genotyping Kit HPV GP. Cytological examination were done by using conventional (Papanicolaou) method and interpreted according to 2001 Bethesda System. Results: The median age of the patients was found 36 and there was no significant difference between the median ages of the HPV DNA negative and positive women. High risk HPV DNA was determined 110 out of 328 patients (33.5%) and multiple types were detected 22.7% of the cases. The most determined types were HPV-16/51/18 and 56 respectively. Abnormal cytology was detected from 21.5% of the 270 patients that were evaluated by pathologist simultaneously. The abnormal cytologic signs of the patients were reported as 48.3% ASCUS, 34.5% LSIL, 7% ASC-H, 7% HSIL and 3.5% AGUS. The HPV DNA positivity of the patients with abnormal cytologic results (50%) were found high significantly comparing the patients with normal cytology (28.3%) (p=0.002). The type 16 was determined 38% and 44% from the patients with abnormal and normal cytology, respectively. Conclusion: The genotyping of HPV plays an important role while the cervical cancer screening programmes have gaining importance globally. The determination of high rates of type 16 from patients with normal cytology proves that cytologic evaluation should be supported by DNA typing and those patients should be followed up closely.